Correlation Between Carbohydrate Antigen 199 and Glycemic Control in Patients with Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and hyperglycemia. Emerging evidence suggests that T2DM is associated with an elevated risk of pancreatic complications, including pancreatic cancer and chronic pancreatitis. Carbohydrate antigen 199 (CA 199), a tumor marker widely used for pancreatic cancer detection, has also been implicated in pancreatic inflammation and tissue damage. This study investigates the relationship between serum CA 199 levels and glycemic control, as measured by hemoglobin A1c (HbA1c), in T2DM patients, while exploring additional hematological and biochemical parameters linked to diabetes progression.
Study Design and Methodology
The retrospective analysis included 527 T2DM patients (286 males, 241 females) and 208 healthy controls (112 males, 96 females) recruited from Tianjin First Center Hospital between 2015 and 2016. Participants with a history of tumors, thyroid disorders, chronic infections, liver disease, anemia, or immune-related conditions were excluded. Blood samples were collected to measure hematological parameters (white blood cells, neutrophils, lymphocytes, platelets, hemoglobin, platelet distribution width [PDW], red blood cell distribution width [RDW]), biochemical markers (total cholesterol [TC], triglycerides [TG], high-density lipoprotein [HDL], low-density lipoprotein [LDL], creatinine), and CA 199 levels. HbA1c was used to stratify patients into two groups: good glycemic control (HbA1c ≤7%) and poor glycemic control (HbA1c >7%).
Laboratory analyses were performed using standardized protocols:
- Hematological parameters: Measured via a Cell-Dyne counter (Abbott, USA).
- CA 199 and HbA1c: Quantified using ELISA kits (Merck, Germany).
- Lipid profiles and creatinine: Analyzed using an Abbott Aeroset auto-analyzer.
Statistical analyses included independent samples t-tests for parametric data, Mann-Whitney U tests for non-parametric data, chi-square tests for categorical variables, and logistic regression to identify predictors of HbA1c. Receiver operating characteristic (ROC) curves evaluated the diagnostic utility of CA 199.
Key Findings
1. Hematological and Biochemical Differences in T2DM Patients
T2DM patients exhibited significant elevations in RDW (13.4% vs. 12.8%, P<0.001), PDW (16.2% vs. 15.6%, P=0.046), and TC (5.1 mmol/L vs. 4.8 mmol/L, P=0.035) compared to healthy controls. These differences suggest impaired erythrocyte and platelet physiology in diabetes, potentially due to chronic hyperglycemia and oxidative stress.
In the HbA1c >7% subgroup, RDW (13.8% vs. 13.1%, P=0.038), PDW (16.5% vs. 15.9%, P=0.039), lymphocyte count (2.1 ×10³/μL vs. 1.8 ×10³/μL, P<0.001), and TC (5.3 mmol/L vs. 4.9 mmol/L, P=0.021) were significantly higher than in the HbA1c ≤7% group. These results highlight the role of poor glycemic control in exacerbating cellular dysfunction and metabolic dysregulation.
2. CA 199 Levels and Association with HbA1c
Serum CA 199 levels were markedly elevated in T2DM patients (43.64 ±18.54 U/mL) compared to controls (13.74 ±11.92 U/mL, P7% group (47.2 ±22.1 U/mL) than in the HbA1c ≤7% group (34.45 ±21.12 U/mL, P=0.015). Regression analysis confirmed a positive correlation between CA 199 and HbA1c (r=0.320, P<0.001) (Figure 1A).
Multivariate logistic regression identified CA 199 (OR=2.146, 95% CI: 1.143–7.613, P<0.001), RDW (OR=1.152, 95% CI: 0.651–3.256, P=0.037), and TC (OR=1.026, 95% CI: 0.893–1.098, P=0.044) as independent predictors of HbA1c levels. ROC curve analysis demonstrated that CA 199 had an area under the curve (AUC) of 0.744 (95% CI: 0.572–0.736, P<0.001) for distinguishing poor glycemic control (Figure 1B).
Mechanistic Insights
CA 199 as a Marker of Pancreatic Inflammation
Chronic hyperglycemia in T2DM induces pancreatic β-cell dysfunction and systemic inflammation. CA 199, a sialylated Lewis blood group antigen, is overexpressed in inflamed or damaged pancreatic tissues. Elevated CA 199 levels in T2DM patients may reflect subclinical pancreatic injury, akin to patterns observed in chronic pancreatitis. This aligns with previous studies showing that 50% of chronic pancreatitis patients develop hyperglycemia due to endocrine dysfunction.
Role of RDW and PDW in Glycemic Control
RDW, a measure of erythrocyte size variability, increases in conditions of oxidative stress and ineffective erythropoiesis. In diabetes, glycation of hemoglobin reduces erythrocyte deformability and lifespan, elevating RDW. Similarly, PDW, an indicator of platelet size heterogeneity, rises in diabetic patients with microvascular complications. The study’s findings corroborate earlier reports linking higher RDW and PDW to poor glycemic control and diabetic complications.
Dyslipidemia and Insulin Resistance
Elevated TC levels in the HbA1c >7% group underscore the interplay between dyslipidemia and insulin resistance. Hyperglycemia promotes lipotoxicity, which exacerbates β-cell dysfunction and systemic inflammation, further impairing glycemic control.
Clinical Implications and Limitations**
The study establishes CA 199 as a potential biomarker for monitoring glycemic control and pancreatic health in T2DM. Elevated CA 199, RDW, and PDW may signal the need for intensified glycemic management to mitigate complications. However, the retrospective design limits causal inference. Prospective studies are required to validate these associations and explore therapeutic interventions targeting inflammation and cellular dysfunction.
doi.org/10.1097/CM9.0000000000000169
Was this helpful?
0 / 0